Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
QuintilesIMS
Cipla
Julphar
Queensland Health
Cantor Fitzgerald
Fish and Richardson
Merck
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,004,968

« Back to Dashboard

Which drugs does patent 6,004,968 protect, and when does it expire?

Patent 6,004,968 protects EPIVIR and EPIVIR-HBV and is included in two NDAs.

Protection for EPIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-four patent family members in forty-three countries.
Summary for Patent: 6,004,968
Title: Pharmaceutical compositions containing lamivudine
Abstract:The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.
Inventor(s): Casey; Warren Michael (Knightdale, NC), Nguyen; Ngoc-Anh Thi (Durham, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:09/044,896
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,004,968

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Viiv Hlthcare EPIVIR lamivudine SOLUTION;ORAL 020596-001 Nov 17, 1995 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,004,968

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9706295Mar 26, 1997

International Family Members for US Patent 6,004,968

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1141 ➤ Try a Free Trial
Argentina 011697 ➤ Try a Free Trial
Austria 295150 ➤ Try a Free Trial
Australia 7208498 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Moodys
Farmers Insurance
Federal Trade Commission
Covington
McKinsey
Accenture
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.